Insulet (BSP:P2OD34) Cyclically Adjusted Revenue per Share: R$3.78 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:P2OD34 Insulet Corp BSP:P2OD34
62 GF Score
Price R$22.68
GF Value R$66.65
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Cyclically Adjusted Revenue per Share?

Insulet BSP:P2OD34 62 Cyclically Adjusted Revenue per Share is R$3.78 as of Jun. 2026. GuruFocus rates BSP:P2OD34 with a GF Score™ of 62/100 and a GF Value™ of R$66.65 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Insulet's adjusted revenue per share for the three months ended in Jun. 2026 was R$59.190. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$3.78 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Insulet's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Insulet was 21.00% per year. The lowest was 3.70% per year. And the median was 19.80% per year.

As of today (2026-08-09), Insulet's current stock price is R$22.68. Insulet's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$3.78. Insulet's Cyclically Adjusted PS Ratio of today is 6.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 6.48. And the median was 18.40.


Insulet  (BSP:P2OD34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Insulet's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22.68/3.78
=6.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 6.48. And the median was 18.40.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Insulet Cyclically Adjusted Revenue per Share Related Terms


Insulet Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Insulet's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Cyclically Adjusted Revenue per Share Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Insulet Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.78

BSP:P2OD34 vs GMED, PEN, BRKR: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Insulet's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's Cyclically Adjusted PS Ratio falls into.


BSP:P2OD34
62GF Score
Insulet Corp BSP:P2OD34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insulet's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=59.19/333.9520*333.9520
=59.190

Current CPI (Jun. 2026) = 333.9520.

Insulet Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.382 241.428 7.445
201612 6.048 241.432 8.366
201703 5.514 243.801 7.553
201706 6.239 244.955 8.506
201709 6.566 246.819 8.884
201712 7.386 246.524 10.005
201803 6.929 249.554 9.272
201806 7.965 251.989 10.556
201809 10.152 252.439 13.430
201812 9.459 251.233 12.573
201903 10.024 254.202 13.169
201906 11.106 256.143 14.480
201909 12.695 256.759 16.512
201912 13.423 256.974 17.444
202003 15.385 258.115 19.905
202006 17.904 257.797 23.193
202009 18.908 260.280 24.260
202012 18.900 260.474 24.232
202103 21.505 264.877 27.113
202106 19.844 271.696 24.391
202109 20.898 274.310 25.442
202112 23.964 278.802 28.704
202203 21.043 287.504 24.443
202206 21.790 296.311 24.558
202209 25.743 296.808 28.965
202212 27.080 296.797 30.470
202303 26.609 301.836 29.440
202306 27.437 305.109 30.031
202309 29.026 307.789 31.493
202312 29.667 306.746 32.298
202403 29.828 312.332 31.893
202406 35.651 314.175 37.895
202409 40.730 315.301 43.139
202412 49.212 315.605 52.073
202503 44.209 319.799 46.166
202506 50.951 322.561 52.750
202509 53.606 324.800 55.116
202512 60.511 324.054 62.359
202603 56.742 330.213 57.384
202606 59.190 333.952 59.190

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$3.78 mean?
Insulet (BSP:P2OD34) has a Cyclically Adjusted Revenue per Share of R$3.78 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insulet and its competitors.
Is Insulet's Cyclically Adjusted Revenue per Share too high?
Insulet's current Cyclically Adjusted Revenue per Share is R$3.78. Overall, Insulet has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Cyclically Adjusted Revenue per Share compare to GMED and PEN?
Insulet's Cyclically Adjusted Revenue per Share of R$3.78 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insulet and its competitors. Insulet's current Cyclically Adjusted Revenue per Share is R$3.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (BSP:P2OD34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$66.65, compared to a current price of R$22.68 — trading 66% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$3.78. Insulet's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Insulet (BSP:P2OD34), the current Cyclically Adjusted Revenue per Share is R$3.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (BSP:P2OD34) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of R$22.68 is trading 66% below its estimated GF Value™ of R$66.65. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for BSP:P2OD34:

  • Cyclically Adjusted Revenue per Share: R$3.78
  • GF Value™: R$66.65 vs. price of R$22.68 (66% below fair value)
  • GF Score™: 62/100

No single metric tells the full story. See the BSP:P2OD34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
62GF Score

Get the complete analysis for BSP:P2OD34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$22.68
Price
R$66.65
GF Value